BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.44
+0.14 (1.85%)
Nov 21, 2024, 1:29 PM EST - Market open
BioCryst Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 412.58 | 331.41 | 270.83 | 157.17 | 17.81 | 48.84 | Upgrade
|
| Revenue Growth (YoY) | 29.92% | 22.37% | 72.31% | 782.38% | -63.53% | 136.45% | Upgrade
|
| Cost of Revenue | 197.47 | 216.65 | 259.89 | 216.07 | 124.64 | 111.17 | Upgrade
|
| Gross Profit | 215.11 | 114.76 | 10.94 | -58.9 | -106.83 | -62.33 | Upgrade
|
| Selling, General & Admin | 249.63 | 213.54 | 159.37 | 118.82 | 62.9 | 37.12 | Upgrade
|
| Operating Expenses | 249.63 | 213.54 | 159.37 | 118.82 | 62.9 | 37.12 | Upgrade
|
| Operating Income | -34.51 | -98.78 | -148.44 | -177.72 | -169.73 | -99.46 | Upgrade
|
| Interest Expense | -98.65 | -108.24 | -99.09 | -59.29 | -14.5 | -11.89 | Upgrade
|
| Interest & Investment Income | 15.64 | 15.78 | 5.13 | 0.06 | 0.53 | 1.93 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.41 | -1.04 | -1.98 | -0.7 | -0.97 | 0.52 | Upgrade
|
| EBT Excluding Unusual Items | -117.93 | -192.28 | -244.38 | -237.65 | -184.67 | -108.9 | Upgrade
|
| Merger & Restructuring Charges | -4.64 | -3.38 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0 | - | - | Upgrade
|
| Asset Writedown | -1.55 | -1.55 | - | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | 3.87 | - | Upgrade
|
| Other Unusual Items | - | -29.02 | - | 55.84 | -2.01 | - | Upgrade
|
| Pretax Income | -124.13 | -226.23 | -244.38 | -181.81 | -182.81 | -108.9 | Upgrade
|
| Income Tax Expense | -0.31 | 0.31 | 2.73 | 2.25 | - | - | Upgrade
|
| Net Income | -123.82 | -226.54 | -247.12 | -184.06 | -182.81 | -108.9 | Upgrade
|
| Net Income to Common | -123.82 | -226.54 | -247.12 | -184.06 | -182.81 | -108.9 | Upgrade
|
| Shares Outstanding (Basic) | 205 | 192 | 186 | 179 | 167 | 116 | Upgrade
|
| Shares Outstanding (Diluted) | 205 | 192 | 186 | 179 | 167 | 116 | Upgrade
|
| Shares Change (YoY) | 8.84% | 3.38% | 3.79% | 7.08% | 44.69% | 12.03% | Upgrade
|
| EPS (Basic) | -0.60 | -1.18 | -1.33 | -1.03 | -1.09 | -0.94 | Upgrade
|
| EPS (Diluted) | -0.60 | -1.18 | -1.33 | -1.03 | -1.09 | -0.94 | Upgrade
|
| Free Cash Flow | -56.73 | -97.31 | -163.2 | -144.54 | -135.62 | -89.93 | Upgrade
|
| Free Cash Flow Per Share | -0.28 | -0.51 | -0.88 | -0.81 | -0.81 | -0.78 | Upgrade
|
| Gross Margin | 52.14% | 34.63% | 4.04% | -37.48% | - | -127.64% | Upgrade
|
| Operating Margin | -8.37% | -29.81% | -54.81% | -113.08% | -952.90% | -203.66% | Upgrade
|
| Profit Margin | -30.01% | -68.36% | -91.24% | -117.11% | -1026.35% | -222.99% | Upgrade
|
| Free Cash Flow Margin | -13.75% | -29.36% | -60.26% | -91.97% | -761.41% | -184.14% | Upgrade
|
| EBITDA | -31.94 | -95.91 | -146.18 | -176.83 | -168.98 | -98.73 | Upgrade
|
| EBITDA Margin | -7.74% | -28.94% | -53.98% | -112.51% | - | -202.17% | Upgrade
|
| D&A For EBITDA | 2.57 | 2.87 | 2.25 | 0.89 | 0.75 | 0.72 | Upgrade
|
| EBIT | -34.51 | -98.78 | -148.44 | -177.72 | -169.73 | -99.46 | Upgrade
|
| EBIT Margin | -8.37% | -29.81% | -54.81% | -113.07% | - | -203.66% | Upgrade
|
| Revenue as Reported | - | - | - | - | 17.81 | 48.84 | Upgrade
|
| Advertising Expenses | - | 14.4 | 14.89 | 5.71 | 6.57 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.